Being Efficient About Efficacy Estimation

Stephen Senn

doi:10.1080/19466315.2012.754726

Being Efficient About Efficacy Estimation

Stephen Senn^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

9 Citations (Scopus)

Abstract

I consider Bob O'Neill's important role in promoting regulatory science and, in particular, through the very influential series of lectures he gave in Basel more than 20 years ago, the effect on statistics in European regulation and ultimately on regulatory science in the United States. I provide a simple model of disappointment in drug development. I consider three approaches to improving efficiency in drug development and conclude that there are simple things we could be doing to reduce the cost with which information is obtained in drug development.

Original language	English
Pages (from-to)	204-210
Number of pages	7
Journal	Statistics in Biopharmaceutical Research
Volume	5
Issue number	3
DOIs	https://doi.org/10.1080/19466315.2012.754726
Publication status	Published - Aug 2013

Keywords

Analysis of covariance
Dichotomies
Flexible designs
Patient-by-treatment interaction
Pharmacogentics
Responder analysis

Access to Document

10.1080/19466315.2012.754726

Cite this

@article{a30a39c1067b4894b374862c65814074,

title = "Being Efficient About Efficacy Estimation",

abstract = "I consider Bob O'Neill's important role in promoting regulatory science and, in particular, through the very influential series of lectures he gave in Basel more than 20 years ago, the effect on statistics in European regulation and ultimately on regulatory science in the United States. I provide a simple model of disappointment in drug development. I consider three approaches to improving efficiency in drug development and conclude that there are simple things we could be doing to reduce the cost with which information is obtained in drug development.",

keywords = "Analysis of covariance, Dichotomies, Flexible designs, Patient-by-treatment interaction, Pharmacogentics, Responder analysis",

author = "Stephen Senn",

year = "2013",

month = aug,

doi = "10.1080/19466315.2012.754726",

language = "English",

volume = "5",

pages = "204--210",

journal = "Statistics in Biopharmaceutical Research",

issn = "1946-6315",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Being Efficient About Efficacy Estimation

AU - Senn, Stephen

PY - 2013/8

Y1 - 2013/8

N2 - I consider Bob O'Neill's important role in promoting regulatory science and, in particular, through the very influential series of lectures he gave in Basel more than 20 years ago, the effect on statistics in European regulation and ultimately on regulatory science in the United States. I provide a simple model of disappointment in drug development. I consider three approaches to improving efficiency in drug development and conclude that there are simple things we could be doing to reduce the cost with which information is obtained in drug development.

AB - I consider Bob O'Neill's important role in promoting regulatory science and, in particular, through the very influential series of lectures he gave in Basel more than 20 years ago, the effect on statistics in European regulation and ultimately on regulatory science in the United States. I provide a simple model of disappointment in drug development. I consider three approaches to improving efficiency in drug development and conclude that there are simple things we could be doing to reduce the cost with which information is obtained in drug development.

KW - Analysis of covariance

KW - Dichotomies

KW - Flexible designs

KW - Patient-by-treatment interaction

KW - Pharmacogentics

KW - Responder analysis

UR - http://www.scopus.com/inward/record.url?scp=84884298857&partnerID=8YFLogxK

U2 - 10.1080/19466315.2012.754726

DO - 10.1080/19466315.2012.754726

M3 - Article

AN - SCOPUS:84884298857

SN - 1946-6315

VL - 5

SP - 204

EP - 210

JO - Statistics in Biopharmaceutical Research

JF - Statistics in Biopharmaceutical Research

IS - 3

ER -

Being Efficient About Efficacy Estimation

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this